MedPath

Radiochemotherapy in association with capecitabine and oxaliplatin in the treatment of pancreatic and biliary tract, unresectable cancer: a dose escalation study - XelOx -P07

Conditions
pancreatic and biliary tract, unresectable cancer
MedDRA version: 9.1Level: LLTClassification code 10033611Term: Pancreatic carcinoma non-resectable
Registration Number
EUCTR2007-004814-15-IT
Lead Sponsor
POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Histologically proved carcinoma of pancreas or biliary tract

measurable disease

age >18 years

performance status (ECOG) 0-1

no previous chemio or radiotherapeutic treatments
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

metastasis

previous radiotherapy or chemiotherapy

renal failure

hepatic failure

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath